Skip to content

Study · Observational study · n = 102 · 2024

5 results

Effectiveness of switching from dipeptidyl peptidase-4 inhibitor to oral glucagon-like peptide-1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching.

Iwamoto H, Kimura T, Fushimi Y, Iwamoto M, Tatsumi F, Sanada J, Iwamoto Y, Katakura Y, Shimoda M, Nakanishi S, Mune T, Kaku K, Kaneto H

Diabetes, obesity & metabolism22 Jul 2024Cited by 1 (Europe PMC)

PMID39039725 (opens in a new tab)DOI10.1111/dom.15784 (opens in a new tab)PepBankPUB-39039725
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In Japanese adults with type 2 diabetes, glycaemic control improved more in the group switched to oral semaglutide than in the DPP-4 inhibitor continuation group over 6 months.

    In plain wordsIn Japanese adults with type 2 diabetes, blood sugar control improved more after switching to oral semaglutide than after staying on a DPP-4 inhibitor.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedGlycaemic control versus DPP-4 inhibitor continuation (study 2)
    Study

    n = 102

    Comparator
    Continued DPP-4 inhibitor
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    In 'study 2', after 1:1 propensity score matching, 51 participants from each group were matched, and glycaemic control as well as body weight management were improved in the switching group compared with the DPP-4 inhibitor continuation group over the 6-month observation period.
    1 context sentence
    Summary · context
    Fifty-nine participants were included, and we compared various clinical parameters between before and after switching from DPP-4 inhibitors to oral semaglutide in 'study 1' (pre-post comparison) and set the control group using the propensity score matching method in 'study 2'.
  2. 02HumanObservational studyEfficacy outcome

    In Japanese adults with type 2 diabetes, body weight management improved more in the group switched to oral semaglutide than in the DPP-4 inhibitor continuation group over 6 months.

    In plain wordsIn Japanese adults with type 2 diabetes, weight control improved more after switching to oral semaglutide than after staying on a DPP-4 inhibitor.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedBody weight management versus DPP-4 inhibitor continuation (study 2)
    Study

    n = 102

    Comparator
    Continued DPP-4 inhibitor
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    In 'study 2', after 1:1 propensity score matching, 51 participants from each group were matched, and glycaemic control as well as body weight management were improved in the switching group compared with the DPP-4 inhibitor continuation group over the 6-month observation period.
    1 context sentence
    Summary · context
    Fifty-nine participants were included, and we compared various clinical parameters between before and after switching from DPP-4 inhibitors to oral semaglutide in 'study 1' (pre-post comparison) and set the control group using the propensity score matching method in 'study 2'.
  3. 03HumanObservational studyEfficacy outcome

    In Japanese adults with type 2 diabetes, HbA1c fell significantly from 7.5% to 7.0% 6 months after switching from a DPP-4 inhibitor to oral semaglutide.

    In plain wordsIn Japanese adults with type 2 diabetes, HbA1c was lower 6 months after switching from a DPP-4 inhibitor to oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c change after switching (study 1)
    Study

    n = 59

    Comparator
    Baseline on DPP-4 inhibitor
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Measurements

    HbA1c
    7.5%
    before switching
    HbA1c
    7%
    6 months after switching

    Source sentences

    Summary
    In 'study 1', 6 months after the switching, the glycated haemoglobin value was significantly reduced from 7.5% to 7.0%, and the body mass index was also decreased from 29.7 kg/m2 to 28.8 kg/m2.
    1 context sentence
    Summary · context
    Fifty-nine participants were included, and we compared various clinical parameters between before and after switching from DPP-4 inhibitors to oral semaglutide in 'study 1' (pre-post comparison) and set the control group using the propensity score matching method in 'study 2'.
  4. 04HumanObservational studyEfficacy outcome

    In Japanese adults with type 2 diabetes, BMI decreased from 29.7 to 28.8 kg/m2 6 months after switching from a DPP-4 inhibitor to oral semaglutide.

    In plain wordsIn Japanese adults with type 2 diabetes, BMI was lower 6 months after switching from a DPP-4 inhibitor to oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI change after switching (study 1)
    Study

    n = 59

    Comparator
    Baseline on DPP-4 inhibitor
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Measurements

    BMI
    29.7 kg/m<sup>2</sup>
    before switching
    BMI
    28.8 kg/m<sup>2</sup>
    6 months after switching

    Source sentences

    Summary
    In 'study 1', 6 months after the switching, the glycated haemoglobin value was significantly reduced from 7.5% to 7.0%, and the body mass index was also decreased from 29.7 kg/m2 to 28.8 kg/m2.
    1 context sentence
    Summary · context
    Fifty-nine participants were included, and we compared various clinical parameters between before and after switching from DPP-4 inhibitors to oral semaglutide in 'study 1' (pre-post comparison) and set the control group using the propensity score matching method in 'study 2'.
  5. 05HumanObservational studyEfficacy outcome

    In Japanese adults with type 2 diabetes, the effects of switching to oral semaglutide were more clearly seen in participants whose glycaemic control was poor.

    In plain wordsIn Japanese adults with type 2 diabetes, switching to oral semaglutide worked more clearly in people whose blood sugar control was poor.

    Peptide
    Semaglutide
    Outcome
    Not applicableEffect size in participants with poor glycaemic control (study 1)
    Study

    n: not reported in source

    Comparator
    Baseline on DPP-4 inhibitor
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oral · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Such effects were more clearly observed in participants whose glycaemic control was poor.
    1 context sentence
    Summary · context
    Fifty-nine participants were included, and we compared various clinical parameters between before and after switching from DPP-4 inhibitors to oral semaglutide in 'study 1' (pre-post comparison) and set the control group using the propensity score matching method in 'study 2'.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.